Anti-Inflammatory Mushrooms for Metabolic Inflammation

Mushrooms and Inflammation

45-70% TNF-alpha reduction

Ganoderma lucidum triterpene extract suppressed TNF-alpha secretion by 45 to 70 percent in LPS-stimulated macrophages, one of the strongest preclinical anti-inflammatory effects documented for any medicinal mushroom.

Dudhgaonkar et al., International Immunopharmacology, 2009

3+ species

reishi, oyster mushroom, Agaricus blazei

NF-kB target

master inflammatory regulator suppressed

Lab vs. clinic gap

human trial results lag behind cell studies

Dudhgaonkar et al., International Immunopharmacology, 2009

View as image ↗

Metabolic inflammation is the chronic, low-grade inflammatory state that accompanies obesity, insulin resistance, and cardiovascular disease. Unlike acute inflammation from an infection or injury, metabolic inflammation simmers without resolution, driven by adipose tissue dysfunction, elevated circulating lipids, and sustained activation of inflammatory signaling cascades like NF-kappaB. Several medicinal mushroom species suppress these exact pathways in laboratory studies, with Ganoderma lucidum triterpenes reducing TNF-alpha secretion by 45 to 70 percent in activated macrophages.^[1]

The preclinical data is compelling. The clinical data is not. That gap between petri dish and patient defines the current state of anti-inflammatory mushroom research for metabolic conditions. For a broader perspective on the best mushrooms for chronic low-grade inflammation, see the companion overview.

What metabolic inflammation is and why mushrooms matter

Metabolic inflammation (sometimes called metaflammation) differs from classical inflammation in three ways. It is low-grade rather than acute. It is systemic rather than localized. And it feeds on itself: inflamed adipose tissue produces cytokines that promote insulin resistance, which causes more fat accumulation, which generates more inflammation.

The molecular drivers are well-characterized. Expanded adipose tissue activates macrophages that produce TNF-alpha, IL-6, and IL-1beta. These cytokines activate the NF-kappaB signaling cascade, which upregulates additional inflammatory genes. C-reactive protein (CRP) rises as a systemic marker. Over years, this cycle contributes to type 2 diabetes, atherosclerosis, non-alcoholic fatty liver disease, and other metabolic disorders.

Kundakovic et al. (2013) reviewed the therapeutic potential of mushrooms for managing metabolic syndrome and found that edible mushrooms, their extracts, polysaccharide fractions, and isolated compounds possessed hypoglycemic, cholesterol-lowering, and anti-inflammatory properties that address multiple metabolic syndrome components simultaneously.^[2] This multi-target activity is what distinguishes mushrooms from single-mechanism pharmaceutical approaches.

Reishi (Ganoderma lucidum): triterpene-driven NF-kappaB suppression

Ganoderma lucidum produces the most studied anti-inflammatory compounds among medicinal mushrooms. The triterpene fraction, rather than the polysaccharide fraction, drives the anti-inflammatory effects.

Dudhgaonkar et al. (2009) isolated the triterpene extract from Ganoderma lucidum (GLT) and tested it against LPS-stimulated RAW264.7 macrophages. GLT markedly suppressed the secretion of TNF-alpha and IL-6 (45 to 70 percent reduction), as well as the inflammatory mediators nitric oxide (NO) and prostaglandin E2 (PGE2).^[1]

The mechanism involved suppression of NF-kappaB activation. GLT inhibited IkappaB-alpha phosphorylation and p65 nuclear translocation, which are the two key steps in NF-kappaB activation. When NF-kappaB cannot enter the nucleus, it cannot turn on inflammatory gene expression. GLT also suppressed AP-1 transcriptional activity, providing a second anti-inflammatory mechanism through a different signaling pathway.^[1]

The polysaccharide fraction of Ganoderma lucidum has separate immunomodulatory properties. Cai et al. (2017) demonstrated that Ganoderma lucidum polysaccharides (GLP) attenuated microglia-mediated neuroinflammation and modulated microglial phagocytosis in both cell culture and animal behavioral models.^[3] While this study focused on neuroinflammation rather than metabolic inflammation, it confirms that Ganoderma polysaccharides can modulate inflammatory responses in different tissue contexts.

The triterpene fraction's mechanism is pharmacologically specific. Unlike broad-spectrum antioxidants that scavenge free radicals non-specifically, GLT directly interfered with the NF-kappaB signaling cascade at defined molecular steps. This precision is what makes the 45 to 70 percent cytokine reduction reproducible across experiments. It also means that the anti-inflammatory effect requires the triterpene fraction specifically, not just any Ganoderma extract.

The distinction between triterpene and polysaccharide fractions matters for supplement selection. A Ganoderma extract standardized for polysaccharides would have different anti-inflammatory properties than one standardized for triterpenes. Hot water extraction favors polysaccharides. Ethanol extraction favors triterpenes. Dual extraction captures both. Most commercial reishi supplements do not specify which fraction dominates or which extraction method was used, making it impossible to predict whether they deliver the triterpene-mediated NF-kappaB suppression documented in the Dudhgaonkar study.

Oyster mushroom (Pleurotus ostreatus): dual pathway inhibition

Jedinak et al. (2011) published the most mechanistically detailed study on oyster mushroom anti-inflammatory activity. They tested an oyster mushroom concentrate (OMC) in both cell culture and an animal model, providing the kind of dual validation that cell-only studies lack.^[4]

In RAW264.7 macrophages stimulated with LPS, OMC dose-dependently inhibited the production of TNF-alpha, IL-6, and IL-12. The mechanism involved suppression of both NF-kappaB and AP-1 signaling pathways. OMC also suppressed LPS-induced expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), two enzymes that produce inflammatory mediators.^[4]

The in vivo component strengthens this finding. OMC reduced inflammation in a mouse ear edema model, confirming that the cell culture effects translate to a living system. The edema model measures swelling caused by inflammatory mediators, providing a functional readout rather than just molecular markers.^[4]

The dual inhibition of NF-kappaB and AP-1 is mechanistically significant because these two transcription factors regulate overlapping but distinct sets of inflammatory genes. NF-kappaB primarily controls TNF-alpha, IL-6, and iNOS expression. AP-1 regulates COX-2, MMP expression, and certain cytokines. Blocking both pathways simultaneously produces broader anti-inflammatory coverage than targeting either alone. This dual mechanism distinguishes oyster mushroom from many single-target anti-inflammatory agents.

Oyster mushrooms are among the most widely consumed edible mushrooms globally, making them a practical dietary source of anti-inflammatory compounds. However, the study used a concentrated extract (OMC) at defined doses, not whole mushroom. Whether the concentrations achievable through dietary consumption of cooked oyster mushrooms reach the levels used in the cell culture experiments (up to 100 micrograms per milliliter) is unknown. The in vivo ear edema result suggests at least some anti-inflammatory activity is achievable through oral dosing in mice, but the equivalent human dose has not been established.

Agaricus blazei: immune rebalancing rather than simple suppression

Agaricus blazei Murill takes a different approach to inflammation. Rather than directly suppressing inflammatory cytokines, it modulates the balance between Th1 (pro-inflammatory) and Th2 (anti-inflammatory) immune responses.

Hetland et al. (2011) reviewed the evidence that Agaricus blazei, rich in immunomodulating beta-glucans, ameliorated Th1/Th2 imbalance and inflammation in both preclinical models and preliminary human studies.^[5] In mouse models of allergy and asthma, Agaricus blazei shifted the immune response away from Th2 dominance (which drives allergic inflammation) toward a more balanced state.

The relevance to metabolic inflammation is indirect but mechanistically plausible. Metabolic inflammation involves macrophage polarization in adipose tissue, with classically activated (M1) macrophages producing inflammatory cytokines like TNF-alpha and IL-6. Alternatively activated (M2) macrophages produce anti-inflammatory cytokines like IL-10 and promote tissue repair. The M1/M2 balance in adipose tissue is a key determinant of whether obesity progresses to metabolic disease. Immune rebalancing agents that shift macrophage polarization toward M2 could theoretically reduce metabolic inflammation, though this specific mechanism has not been tested directly with Agaricus blazei in adipose tissue models.

Hetland et al. (2020) expanded this review to include three related basidiomycete mushrooms: Agaricus blazei, Hericium erinaceus, and Grifola frondosa. All three showed anti-inflammatory properties in preclinical studies, though through different mechanisms. Hericium erinaceus (lion's mane) demonstrated anti-inflammatory effects primarily in neural tissue, while Grifola frondosa (maitake) showed immunomodulatory activity through beta-glucan-mediated macrophage activation.^[6]

The metabolic syndrome connection

Metabolic syndrome links inflammation to a cluster of conditions: central obesity, hyperglycemia, dyslipidemia, and hypertension. Mushrooms address this syndrome through multiple mechanisms simultaneously, not just anti-inflammatory activity.

Ganesan et al. (2018) reviewed the anti-obesity effects of medicinal and edible mushrooms, identifying that excess visceral fat mass generates chronic inflammation-based cardiovascular pathophysiology. Mushroom-derived compounds attenuated this through antioxidant activity that reduced oxidative stress in adipose tissue, direct effects on lipid metabolism through AMPK activation, and suppression of adipocyte differentiation and lipid accumulation.^[7]

Tung et al. (2020) specifically reviewed edible mushrooms as agents to combat metabolic syndrome, noting that mushrooms contain biologically active compounds including polysaccharides, beta-glucans, alkaloids, steroids, polyphenols, and terpenoids that collectively act on multiple metabolic targets. The review emphasized that mushroom fiber and low-fat content provide additional metabolic benefits beyond their bioactive compound content.^[8]

The multi-mechanism approach is conceptually attractive because metabolic syndrome is itself multi-factorial. A single compound that reduces inflammation, lowers lipids, and improves insulin sensitivity would address the syndrome more comprehensively than targeting any single pathway. Whether mushroom extracts achieve this in humans at dietary or supplemental doses is the unresolved question. For related research on specific inflammatory biomarkers, see medicinal mushrooms and CRP reduction and mushrooms and C-reactive protein.

The preclinical-clinical gap

The most important finding in this field may be the one researchers did not expect. A 2025 GRADE-assessed meta-analysis of 17 randomized controlled trials (971 participants) of Ganoderma lucidum supplementation found no significant effect on inflammatory markers in human participants, and rated the certainty of that evidence as very low across all outcomes.^[9] This stands in sharp contrast to the pronounced TNF-alpha reductions documented in cell culture by Dudhgaonkar et al. (2009).^[1]

The Preclinical–Clinical Gap

Strong in the Dish, Silent in the Clinic

The mechanism is not in doubt — mushroom compounds suppress NF-kB and cut cytokine output in cells and animals. What is unresolved is whether any of that survives digestion and reaches human tissue. Reading the two tiers together shows exactly where the evidence breaks down: not at the mechanism, but at delivery.

The preclinical figures come from purified fractions applied directly to cells at defined concentrations [1][4][5]; the clinical result pools oral supplementation across 17 human trials [9]. The unresolved question is not whether these compounds suppress inflammation — they do — but whether oral dosing delivers them to target tissue at effective concentrations. No pharmacokinetic data yet answers that.

Evidence synthesis; tiers from refs [1][4][5][9] (see references)

Human Evidence

Jafari et al. (2025) · Food Science & Nutrition

Population

971 participants across 17 RCTs (healthy, at-risk, and chronic-disease adults)

Intervention

Ganoderma lucidum supplementation, 200–11,200 mg/day for 1–24 weeks

Finding

No significant effect on inflammatory markers, lipid profile, fasting glucose, or blood pressure. Modest reductions appeared only in BMI, creatinine, glutathione peroxidase, and heart rate.

null GRADE certainty of evidence rated very low across all outcomes — the pooled null result is itself low-confidence, not a definitive refutation.

Jafari et al., Food Science & Nutrition, 2025 (GRADE-assessed meta-analysis) [9]

Several factors may explain this gap. Cell culture studies use purified compounds at defined concentrations applied directly to cells. Oral supplementation involves digestion, absorption (which varies by compound), first-pass metabolism, serum protein binding, and tissue distribution, all of which can reduce the effective concentration reaching target cells. The doses used in cell culture may simply not be achievable in vivo through oral administration.

Additionally, LPS-stimulated macrophages in a dish produce inflammatory cytokines at levels far above baseline human physiology. Reducing TNF-alpha in a system with artificially elevated levels is mechanistically different from reducing TNF-alpha in a person with mildly elevated chronic inflammation.

This does not invalidate the preclinical research. It means the mechanism is real but the delivery challenge is unsolved. The triterpenes and polysaccharides from reishi, oyster mushroom, and Agaricus blazei genuinely suppress NF-kappaB signaling and reduce cytokine production in controlled systems. Whether they can do so in living humans at feasible doses remains an open question.

The field needs pharmacokinetic studies that measure actual tissue concentrations of triterpenes and polysaccharides after oral mushroom supplementation. Without knowing whether the active compounds reach target tissues at effective concentrations, the preclinical-clinical gap cannot be bridged. It is equally possible that the compounds are absorbed but rapidly metabolized, that they reach tissues but at sub-therapeutic concentrations, or that the in vitro models simply do not reflect the complexity of chronic metabolic inflammation in humans. For the broader picture of cross-species evidence, see mushrooms for chronic inflammation: cross-species research. For the neuroinflammation angle, see ALS and neuroinflammation: can mushrooms help?

The Bottom Line

Multiple mushroom species suppress NF-kappaB signaling and reduce inflammatory cytokines in cell culture and animal models, with Ganoderma lucidum triterpenes achieving 45 to 70 percent TNF-alpha reduction in macrophages. Oyster mushroom concentrate inhibited both NF-kappaB and AP-1 pathways with in vivo confirmation. Agaricus blazei modulates Th1/Th2 balance rather than directly suppressing inflammation. Despite strong preclinical evidence, human clinical trials have not consistently replicated these inflammatory marker reductions, highlighting a delivery and dosing gap that remains unresolved.

Frequently Asked Questions

What mushrooms are best for reducing inflammation?

Reishi (Ganoderma lucidum) has the strongest preclinical evidence, with its triterpene extract suppressing TNF-alpha by 45 to 70 percent and IL-6 in activated macrophages (Dudhgaonkar et al., 2009). Oyster mushroom (Pleurotus ostreatus) inhibited NF-kappaB and AP-1 pathways with in vivo confirmation (Jedinak et al., 2011). Agaricus blazei modulates immune balance rather than directly suppressing inflammation. All evidence is primarily preclinical.

Can mushrooms help with metabolic syndrome?

Preclinical and review evidence suggests mushrooms address multiple metabolic syndrome components: inflammation, dyslipidemia, hyperglycemia, and obesity. Kundakovic et al. (2013) reviewed evidence that mushroom extracts and polysaccharides possess hypoglycemic, cholesterol-lowering, and anti-inflammatory properties. However, human clinical trials have not consistently shown significant reductions in inflammatory markers like CRP or TNF-alpha.

How do mushrooms reduce inflammation?

The primary mechanism is suppression of NF-kappaB, the master inflammatory transcription factor. Ganoderma lucidum triterpenes block IkappaB-alpha phosphorylation and p65 nuclear translocation, preventing inflammatory gene expression. Oyster mushroom additionally inhibits AP-1 signaling. Agaricus blazei works differently, rebalancing the Th1/Th2 immune ratio rather than directly blocking inflammatory pathways.

Does reishi mushroom lower CRP levels?

In cell culture, Ganoderma lucidum triterpenes reduce upstream inflammatory cytokines (TNF-alpha, IL-6) that drive CRP production. However, a 2025 GRADE-assessed meta-analysis of 17 randomized controlled human trials (971 participants) found no significant effect of Ganoderma lucidum supplementation on inflammatory markers, and rated the certainty of that evidence as very low (Jafari et al., 2025). The preclinical mechanisms are real, but oral supplementation may not deliver sufficient concentrations to target tissues.

Is oyster mushroom anti-inflammatory?

Yes, in laboratory studies. Jedinak et al. (2011) showed that oyster mushroom concentrate dose-dependently inhibited TNF-alpha, IL-6, and IL-12 production in macrophages by blocking NF-kappaB and AP-1 signaling. The anti-inflammatory effect was confirmed in a mouse ear edema model. Whether dietary consumption of oyster mushrooms delivers anti-inflammatory concentrations in humans has not been studied.

Which part of reishi is anti-inflammatory?

The triterpene fraction, not the polysaccharide fraction, drives Ganoderma lucidum's direct anti-inflammatory effects. Dudhgaonkar et al. (2009) specifically isolated the triterpene extract and showed it suppressed TNF-alpha, IL-6, NO, and PGE2 through NF-kappaB inhibition. The polysaccharide fraction has separate immunomodulatory properties. Most commercial reishi supplements do not specify which fraction is dominant.

Sources & References

1. 1RTHM-00152·Dudhgaonkar, Shailesh et al. (2009). “Suppression of the inflammatory response by triterpenes isolated from the mushroom Ganoderma lucidum..” International immunopharmacology.Study breakdown →PubMed →↩
2. 2RTHM-00294·Kundaković, Tatjana et al. (2013). “Therapeutic properties of mushrooms in managing adverse effects in the metabolic syndrome..” Current topics in medicinal chemistry.Study breakdown →PubMed →↩
3. 3RTHM-00462·Cai, Qing et al. (2017). “Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response..” Journal of neuroinflammation.Study breakdown →PubMed →↩
4. 4RTHM-00219·Jedinak, Andrej et al. (2011). “Anti-inflammatory activity of edible oyster mushroom is mediated through the inhibition of NF-κB and AP-1 signaling..” Nutrition journal.Study breakdown →PubMed →↩
5. 5RTHM-00215·Hetland, Geir et al. (2011). “The Mushroom Agaricus blazei Murill Elicits Medicinal Effects on Tumor, Infection, Allergy, and Inflammation through Its Modulation of Innate Immunity and Amelioration of Th1/Th2 Imbalance and Inflammation..” Advances in pharmacological sciences.Study breakdown →PubMed →↩
6. 6RTHM-00620·Hetland, Geir et al. (2020). “Antitumor, Anti-Inflammatory and Antiallergic Effects of Agaricus blazei Mushroom Extract and the Related Medicinal Basidiomycetes Mushrooms, Hericium erinaceus and Grifola frondosa: A Review of Preclinical and Clinical Studies..” Nutrients.Study breakdown →PubMed →↩
7. 7RTHM-00508·Ganesan, Kumar et al. (2018). “Anti-Obesity Effects of Medicinal and Edible Mushrooms..” Molecules (Basel.Study breakdown →PubMed →↩
8. 8RTHM-00660·Tung, Yu-Tang et al. (2020). “Edible Mushrooms: Novel Medicinal Agents to Combat Metabolic Syndrome and Associated Diseases..” Current pharmaceutical design.Study breakdown →PubMed →↩
9. 9RTHM-02098·Jafari, Ali et al. (2025). “The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials..” Food science & nutrition.Study breakdown →PubMed →↩